文献速递疼痛医学术前评估与围术期医学

多部位慢性疼痛与常见疾病及生物标志物的遗传学关联:基于UK Biobank数据的孟德尔随机化研究

Genetic insights into associations of multisite chronic pain with common diseases and biomarkers using data from the UK Biobank.
PubMed 文献 · Br J Anaesth · 2023-12-15

该研究利用UK Biobank数据,通过单变量和多变量孟德尔随机化分析,探讨多部位慢性疼痛(MCP)与36种常见疾病的关联,并评估4774种血浆蛋白表达对MCP的潜在效应。研究发现MCP对精神神经发育、心血管、呼吸、关节病、2型糖尿病和胆石症等有实质性影响,并识别出S100A6、DOCK9、铁蛋白、铁蛋白轻链、PTN9和NEUG六个新生物标志物,其中S100A6、PTN9、NEUG和铁蛋白轻链因未预测到显著副作用而成为有前景的干预靶点。

要点

  • MCP与多种系统疾病相关,包括抑郁、ADHD、心梗、冠心病、心衰、哮喘、COPD、睡眠呼吸暂停、关节病、2型糖尿病和胆石症。
  • 遗传预测的S100A6、DOCK9、铁蛋白和铁蛋白轻链水平升高与MCP风险增加相关,而PTN9和NEUG与MCP风险降低相关。
  • 遗传抑制DOCK9增加21种疾病风险,而S100A6、PTN9、NEUG和铁蛋白轻链干预相对安全,是有前景的MCP预防靶点。

核心结论

  • 多部位慢性疼痛对覆盖多个生理系统的健康状况有影响,并识别出六个新的干预生物标志物。
  • S100A6、PTN9、NEUG和铁蛋白轻链是有前景的MCP预防靶点,因研究未预测到显著副作用。

研究设计与样本

  • 研究采用单变量和多变量孟德尔随机化分析,使用UK Biobank数据调查MCP与36种常见疾病的关联。
  • 利用现有血浆蛋白定量性状位点数据估计4774种蛋白表达对MCP的潜在效应。
  • 对显著生物标志物进行全表型孟德尔随机化,涉及1658种结局以预测安全性。

主要发现

  • MCP对精神神经发育特质(重度抑郁和注意缺陷多动障碍)、心血管疾病(心肌梗死、冠状动脉疾病和心力衰竭)、呼吸结局(哮喘、慢性阻塞性肺疾病和睡眠呼吸暂停)、关节病、2型糖尿病和胆石症有实质性影响。
  • 遗传预测的S100A6、DOCK9、铁蛋白和铁蛋白轻链水平较高与MCP风险相关,而PTN9和NEUG与MCP风险降低相关。
  • Phe-MR结果表明遗传抑制DOCK9增加21种疾病风险,而其他生物标志物干预相对安全。

临床怎么用

  • 对于多部位慢性疼痛患者,应关注其精神神经发育、心血管、呼吸、关节、代谢和胆道系统共病的风险评估。
  • S100A6、PTN9、NEUG和铁蛋白轻链可作为未来预防MCP的潜在干预靶点,但需进一步临床验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Chronic pain is a common, complex, and challenging condition, for which specialised healthcare is required. We investigated the relationship between multisite chronic pain (MCP) and different disease traits identify safe biomarker interventions that can prevent MCP. METHODS: Univariable and multivariable Mendelian randomisation (MR) analysis were conducted to investigate associations between MCP and 36 common diseases in the UK Biobank. Subsequently, we estimated the potential effect of expression of 4774 proteins on MCP utilising existing plasma protein quantitative trait locus data. For the significant biomarkers, we performed phenome-wide MR (Phe-MR) with 1658 outcomes to predict potential safety profiles linked to biomarker intervention. RESULTS: Multisite chronic pain had a substantial impact on psychiatric and neurodevelopmental traits (major depression and attention deficit hyperactivity disorder), cardiovascular diseases (myocardial infarction, coronary artery disease, and heart failure), respiratory outcomes (asthma, chronic obstructive pulmonary disease, and sleep apnoea), arthropathies, type 2 diabetes mellitus, and cholelithiasis. Higher genetically predicted levels of S100A6, DOCK9, ferritin, and ferritin light chain were associated with a risk of MCP, whereas PTN9 and NEUG were linked to decreased MCP risk. Phe-MR results suggested that genetic inhibition of DOCK9 increased the risk of 21 types of disease, whereas the other biomarker interventions were relatively safe. CONCLUSIONS: We established that MCP has an effect on health conditions covering various physiological systems and identified six novel biomarkers for intervention. In particular, S100A6, PTN9, NEUG, and ferritin light chain represent promising targets for MCP prevention, as no significant side-effects were predicted in our study.

来源:Br J Anaesth,查看原文。版权归原作者所有。

引用

  1. Chen Y, Sun Y, Wang L, et al. Genetic insights into associations of multisite chronic pain with common diseases and biomarkers using data from the UK Biobank. Br J Anaesth. 2023. PMID: 38104003. doi:10.1016/j.bja.2023.11.007

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。